Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22619559 | 0.86 | MAPT (0.64) | HTTMAPTRAB9ANPC1POLB | |
| SCHEMBL9570572 | 0.86 | HTT (0.71) | HTTMAPTRAB9APOLBSMN1; SMN2 | |
| SCHEMBL9570664 | 0.86 | HTT (0.71) | HTTMAPTRAB9APOLBSMN1; SMN2 | |
| SCHEMBL7356605 | 0.85 | HTT (0.69) | HTTMAPTRAB9ASMN1; SMN2KMT2A | |
| SCHEMBL13652531 | 0.84 | MAPT (0.66) | HTTMAPTRAB9ANPC1POLB | |
| SCHEMBL28527575 | 0.83 | ALDH1A1 (0.63) | HTTMAPTRAB9ANPC1POLB | |
| SCHEMBL11684715 | 0.83 | MAPT (0.60) | HTTMAPTRAB9ANPC1POLB | |
| SCHEMBL22192215 | 0.82 | NPC1 (0.86) | MAPTRAB9ANPC1POLBSMN1; SMN2 | |
| SCHEMBL4980566 | 0.81 | GAA (0.64) | HTTMAPTRAB9ANPC1POLB | |
| SCHEMBL1064813 | 0.81 | KMT2A (0.71) | HTTMAPTRAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6293719-A | — | — | None | — | — | JP | disclosed |
| EP-4398037-A1 | COMPOUND FOR FORMING METAL-CONTAINING FILM, COMPOSITION FOR FORMING METAL-CONTAINING FILM, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-07-10 | — | — | EP | disclosed |
| US-11833162-B2 | Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2023-12-05 | — | — | US | disclosed |
| EP-3700911-B1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2023-09-06 | — | — | EP | disclosed |
| CN-111511750-B | Macrocyclic derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2023-06-13 | — | — | CN | disclosed |
| EP-3700911-A1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier SAS (FR) | 2020-09-02 | — | — | EP | disclosed |
| US-20200253993-A1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2020-08-13 | — | — | US | disclosed |
| CN-111511750-A | Novel macrocyclic derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2020-08-07 | — | — | CN | disclosed |
| WO-2019053617-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-03-21 | — | — | WO | disclosed |
| US-7576034-B2 | Crosslinked three-dimensional polymer network, method for preparing same, support material comprising same and uses thereof | EKA CHEMICALS AB (SE) | 2009-08-18 | — | — | US | disclosed |
| EP-0934266-A1 | CROSS-LINKERS FOR CROSS-LINKABLE OPTICAL POLYCARBONATES | Akzo Nobel N.V. (NL) | 1999-08-11 | — | — | EP | disclosed |
| US-5866611-A | PHENOXYPROPYLAMINE INHIBITORS OF SQUALENE SYNTHESE, USEFUL IN TREATING DISEASES IN WHICH A LOWERING OF CHOLESTEROL IS DESIRABLE. | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| WO-1998017644-A1 | CROSS-LINKERS FOR CROSS-LINKABLE OPTICAL POLYCARBONATES | AKZO NOBEL N.V. (NL) | 1998-04-30 | — | — | WO | disclosed |
| JP-H06293719-A | PRODUCTION OF PRIMARY AMINE HAVING THERMOSETTING GROUP | KANEGAFUCHI CHEM IND CO LTD | 1994-10-21 | — | — | JP | disclosed |
| EP-0589018-A1 | AMINES AS INHIBITORS OF SQUALENE SYNTHASE | ZENECA LIMITED (GB) | 1994-03-30 | — | — | EP | disclosed |
| WO-1993020807-A1 | AMINES AS INHIBITORS OF SQUALENE SYNTHASE | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| EP-0257391-A2 | 5-Substituted-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2-methylisoxazolidines | FISONS CORPORATION (US) | 1988-03-02 | — | — | EP | disclosed |
| EP-0257351-A2 | 3-Phenyl-3-(1H-1,2,4-triazol-1-ylmethyl)-5-substituted-2-methyl-isoxazolidines | FISONS CORPORATION (a Massachusetts corporation) (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4727157-A | 3-(Substituted phenyl)-3-(1H-1,2,4-triazol-1-yl)methyl-2-methyl-5-[(substituted phenoxy)methyl]isoxazolidine derivatives | PENNWALT CORPORATION (US) | 1988-02-23 | — | — | US | disclosed |
| US-4723021-A | Substituted 5-(phenoxyalkyl)-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2-methylisoxazolidines | PENNWALT CORPORATION (US) | 1988-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833162-B2 | Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same | C1R, F12, RDX | HTT 1693/4885MAPT 3294/4885RAB9A 1230/4885 |
| US-20200253993-A1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | C1R, RDX, F12 | HTT 2528/4885MAPT 3590/4885RAB9A 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.